Addition of Biphasic Insulin Aspart 30 to Rosiglitazone in Type 2 Diabetes Mellitus That Is Poorly Controlled with Glibenclamide Monotherapy

Itamar Raz, Ulrik Mouritzen, Julius Vaz, Tommy Hershkovitz, Julio Wainstein, Ilana Harman-Boehm

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The incidence of type 2 diabetes mellitus (DM) is rapidly increasing worldwide. Results from large-scale studies show that tight blood glucose (BG) control improves the outcome of patients with type 2 DM. Objective: This trial assessed the short-term efficacy and tolerability of adding a thiazolidinedione (rosiglitazone [ROS]) to existing sulfonylurea (SU) therapy (glibenclamide) compared with switching to combination treatment with a premixed insulin (biphasic insulin aspart 30 [BIAsp 30], a rapid-acting insulin analog) and the thiazolidinedione in a select group of patients with type 2 DM whose metabolic control was inadequate with SU monotherapy. Methods: In this 6-week, multicenter, open-label, parallel-group trial, patients with type 2 DM whose BG level was not adequately controlled with glibenclamide monotherapy (glycosylated hemoglobin [HbA1c] 8%-13%) were randomized either to replace glibenclamide with BIAsp 30 (individually titrated dosages starting with 6-8 U BID) plus rosiglitazone (4 mg once daily) (BIAsp 30 + ROS group) or to add rosiglitazone (4 mg once daily) to their pretrial doses of glibenclamide (GLIB + ROS group). Patients measured their BG levels immediately before each of the 3 main meals, 90 minutes after the start of each meal, and at bedtime, and mean BG levels were calculated at weeks 0 (baseline), 1, 2, 4, 6, and at 2-week follow-up (week 8). The primary end point was change in mean daily BG level during treatment. Secondary end points included preprandial, postprandial, and bedtime BG levels; serum fructosamine level; HbA1c; and fasting BG level, which were measured at each study visit. Tolerability was assessed using hematologic and biochemical parameters, vital signs, and physical examination. Results: Forty-nine patients (32 men, 17 women; mean [SD] age, 59. 1 [8.9] years; mean [SD] body mass index, 27.7 [3.7] kg/m2) participated in the study. A significant difference was found between treatments in the change in mean daily BG level from baseline to week 6 (P = 0.01). After the 6-week treatment period, change in mean serum fructosamine level was significantly greater for BIAsp 30 + ROS compared with GLIB + ROS (P = 0.02). HbA1c decreased in both treatment groups from baseline to study end, but the difference between groups was nonsignificant. The changes in fasting BG from baseline to study end also were nonsignificant between groups. Both combinations were well tolerated. Conclusions: This short-term study in patients with type 2 DM whose BG level was poorly controlled with glibenclamide monotherapy suggests that switching to a combination of BIAsp 30 + ROS was efficacious and well tolerated and provided an alternative to adding rosiglitazone to existing glibenclamide treatment. The study also suggests that BIAsp 30 may be associated with greater improvements in short-term metabolic control.

Original languageEnglish
Pages (from-to)3109-3123
Number of pages15
JournalClinical Therapeutics
Volume25
Issue number12
DOIs
StatePublished - Dec 2003
Externally publishedYes

Keywords

  • BIAsp 30
  • Glycemic control
  • Type 2 diabetes

Fingerprint

Dive into the research topics of 'Addition of Biphasic Insulin Aspart 30 to Rosiglitazone in Type 2 Diabetes Mellitus That Is Poorly Controlled with Glibenclamide Monotherapy'. Together they form a unique fingerprint.

Cite this